Skip to main content
. 2022 Sep 13;25(10):105127. doi: 10.1016/j.isci.2022.105127

Figure 6.

Figure 6

Lyophilized mAb formulation cake appearance

Representative lyophilizates for 10 mg/mL formulations (upper row) and 50 mg/mL (lower row) formulations. FCD only HPBCD mAb formulation, FCD/S: mAb containing HPBCD in combination with sucrose, FCD/P/S: mAb formulation with HPBCD, PVP and sucrose (Haeuser et al., 2019) this image was taken from open access journal Pharmaceutics MDPI: https://doi.org/10.3390/pharmaceutics11110616.